Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JKB-133
- Development stage
- Preclinical
- Lead developer
- TaiwanJ Pharmaceuticals
- Modality
- Small Molecules
01
Overview
JKB-133 is a second-generation small molecule and long-acting antagonist of toll-like receptor 4 (TLR4), developed primarily by TaiwanJ Pharmaceuticals. It is designed as an anti-inflammatory and hepatoprotective agent targeting immune-mediated and metabolic liver diseases. The drug acts by antagonizing TLR4, thereby modulating immune responses implicated in chronic liver inflammation and fibrosis. Its main indications under investigation are autoimmune hepatitis and nonalcoholic steatohepatitis (NASH). As of the latest updates, JKB-133 remains in preclinical development with no reported clinical trial results or regulatory approvals[1][2][3].
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on JKB-133.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JKB-133.